Cell Source, Inc. (CLCS)
USD 0.28
(-16.67%)
USD 0.28
(-16.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.32 Million USD | 3.59% |
| 2022 | 4.17 Million USD | 3.9% |
| 2021 | 4.01 Million USD | 10.46% |
| 2020 | 3.63 Million USD | -4.39% |
| 2019 | 3.8 Million USD | 89.68% |
| 2018 | 2 Million USD | -12.5% |
| 2017 | 2.29 Million USD | -1.11% |
| 2016 | 2.31 Million USD | -0.08% |
| 2015 | 2.32 Million USD | -42.77% |
| 2014 | 4.05 Million USD | 15722.14% |
| 2013 | 25.62 Thousand USD | 1450.07% |
| 2012 | 1653.28 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.13 Million USD | 31.37% |
| 2024 Q2 | 1.19 Million USD | 4.88% |
| 2023 Q3 | 995.38 Thousand USD | 9.93% |
| 2023 FY | 4.18 Million USD | 0.18% |
| 2023 Q4 | 866.35 Thousand USD | -12.96% |
| 2023 Q1 | 1.41 Million USD | 31.96% |
| 2023 Q2 | 905.46 Thousand USD | -36.03% |
| 2022 Q2 | 1.03 Million USD | -1.79% |
| 2022 FY | 4.17 Million USD | 3.9% |
| 2022 Q3 | 1.01 Million USD | -1.72% |
| 2022 Q1 | 1.05 Million USD | 79.4% |
| 2022 Q4 | 1.07 Million USD | 5.58% |
| 2021 Q4 | 586.78 Thousand USD | -55.39% |
| 2021 FY | 4.01 Million USD | 10.46% |
| 2021 Q2 | 995.09 Thousand USD | -11.26% |
| 2021 Q3 | 1.31 Million USD | 32.18% |
| 2021 Q1 | 1.12 Million USD | 34.18% |
| 2020 Q4 | 835.72 Thousand USD | -28.3% |
| 2020 Q1 | 733.33 Thousand USD | 56.84% |
| 2020 Q2 | 903.33 Thousand USD | 23.18% |
| 2020 FY | 3.63 Million USD | -4.39% |
| 2020 Q3 | 1.16 Million USD | 29.04% |
| 2019 FY | 3.8 Million USD | 89.68% |
| 2019 Q1 | 1.17 Million USD | 170.15% |
| 2019 Q2 | 729.9 Thousand USD | -37.67% |
| 2019 Q3 | 1.43 Million USD | 96.83% |
| 2019 Q4 | 467.56 Thousand USD | -67.46% |
| 2018 Q2 | 423.9 Thousand USD | -35.78% |
| 2018 FY | 2 Million USD | -12.5% |
| 2018 Q4 | 433.47 Thousand USD | -11.29% |
| 2018 Q3 | 488.64 Thousand USD | 15.27% |
| 2018 Q1 | 660.11 Thousand USD | 8.67% |
| 2017 Q1 | 483.59 Thousand USD | -10.78% |
| 2017 Q3 | 555.13 Thousand USD | -14.15% |
| 2017 Q2 | 646.62 Thousand USD | 33.71% |
| 2017 FY | 2.29 Million USD | -1.11% |
| 2017 Q4 | 607.44 Thousand USD | 9.42% |
| 2016 Q1 | 644.67 Thousand USD | 4.43% |
| 2016 Q2 | 530.16 Thousand USD | -17.76% |
| 2016 FY | 2.31 Million USD | -0.08% |
| 2016 Q3 | 601.73 Thousand USD | 13.5% |
| 2016 Q4 | 542.02 Thousand USD | -9.92% |
| 2015 FY | 2.32 Million USD | -42.77% |
| 2015 Q4 | 617.34 Thousand USD | 12.42% |
| 2015 Q3 | 549.13 Thousand USD | -3.28% |
| 2015 Q1 | 587.74 Thousand USD | -62.07% |
| 2015 Q2 | 567.73 Thousand USD | -3.4% |
| 2014 Q1 | 11.89 Thousand USD | -29.06% |
| 2014 Q3 | 715.29 Thousand USD | -29.68% |
| 2014 Q2 | 1.01 Million USD | 8449.15% |
| 2014 FY | 4.05 Million USD | 15722.14% |
| 2014 Q4 | 1.54 Million USD | 116.63% |
| 2013 Q4 | 16.77 Thousand USD | 614.35% |
| 2013 Q3 | 2348.00 USD | -99.53% |
| 2013 Q2 | 496.28 Thousand USD | 10209.29% |
| 2013 FY | 25.62 Thousand USD | 1450.07% |
| 2013 Q1 | 4814.00 USD | 0.0% |
| 2012 FY | 1653.28 USD | 0.0% |
| 2012 Q3 | 24.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -223.891% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 14.214% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 85.364% |
| Nascent Biotech, Inc. | 2.22 Million USD | -93.972% |
| Rebus Holdings, Inc. | 664 Thousand USD | -551.408% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 88.39% |
| Qrons Inc. | 643.67 Thousand USD | -571.975% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1010.299% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 92.47% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -941.05% |
| Skye Bioscience, Inc. | 13.54 Million USD | 68.073% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 95.016% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 12.049% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1552.624% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.948% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -48.32% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -187.992% |
| Mesoblast Limited | 5.9 Million USD | 26.714% |
| Marizyme, Inc. | 19.23 Million USD | 77.519% |
| Genus plc | 147.7 Million USD | 97.072% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 50.732% |
| Pharming Group N.V. | 225.49 Million USD | 98.082% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -111.126% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -222.415% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 48.131% |
| ContraFect Corporation | 56.88 Million USD | 92.397% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 1.89% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -192.5% |
| IMV Inc. | 37.7 Million USD | 88.53% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -55.01% |
| MultiCell Technologies, Inc. | 567.42 USD | -762182.965% |
| ONE Bio Corp. | 6.44 Million USD | 32.877% |
| Accustem Sciences Inc. | 3.74 Million USD | -15.453% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.967% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -713.093% |
| Q BioMed Inc. | 3.43 Million USD | -25.86% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 82.499% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -64.617% |
| Biomind Labs Inc. | 994.18 Thousand USD | -335.066% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 95.645% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -145.803% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 35.616% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -132.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 17401.384% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 72.984% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -135.701% |
| GB Sciences, Inc. | 1.42 Million USD | -204.493% |
| Alpha Cognition Inc. | 9.7 Million USD | 55.435% |
| HST Global, Inc. | 140.9 Thousand USD | -2969.646% |
| CSL Limited | 3.44 Billion USD | 99.875% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -284.506% |
| Halberd Corporation | 74.84 Thousand USD | -5679.303% |
| Enzolytics Inc. | 2.17 Million USD | -98.455% |
| Agentix Corp. | 1.37 Million USD | -215.315% |
| Resverlogix Corp. | 12.71 Million USD | 65.974% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -18.48% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.718% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -314.305% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -79.853% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -173.868% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -27.03% |
| AVAX Technologies, Inc. | 7.31 Million USD | 40.832% |
| Zenith Capital Corp. | 8.94 Million USD | 51.634% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.476% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -24728.345% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -76.162% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2421.935% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -125.172% |
| Kadimastem Ltd | 2.41 Million USD | -79.467% |
| Helix BioMedix, Inc. | 1.97 Million USD | -119.334% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 60.197% |
| BioStem Technologies, Inc. | 22.97 Million USD | 81.174% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2283.308% |
| LadRx Corporation | 3.81 Million USD | -13.473% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -368.359% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -368.359% |
| NovAccess Global Inc. | 2.46 Million USD | -75.345% |
| Affymax, Inc. | 39.38 Million USD | 89.018% |
| Itoco Inc. | 919.14 Thousand USD | -370.585% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2.051% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -286.537% |
| Mobile Lads Corp. | 554.54 Thousand USD | -679.98% |
| CytoDyn Inc. | 18.05 Million USD | 76.047% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -17085.212% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1865.37% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -204.646% |
| SYBLEU INC | 160.87 Thousand USD | -2588.621% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -138.138% |
| International Stem Cell Corporation | 5.27 Million USD | 17.941% |
| Bioxytran, Inc. | 3.82 Million USD | -13.225% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -8116.531% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -21162.085% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 88.073% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -167.327% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -487.815% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -39.034% |
| Neutra Corp. | 243.82 Thousand USD | -1673.984% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 75.223% |
| PureTech Health plc | 144.59 Million USD | 97.009% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 78.89% |
| IXICO plc | 4.7 Million USD | 8.108% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 50.832% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.327% |
| CSL Limited | 3.89 Billion USD | 99.889% |
| Cellectis S.A. | 97.32 Million USD | 95.556% |